Compare PAR & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | FTRE |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | PAR | FTRE |
|---|---|---|
| Price | $37.73 | $17.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $64.00 | $12.64 |
| AVG Volume (30 Days) | 475.9K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $440,451,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $30.40 | $3.17 |
| Revenue Next Year | $12.01 | $0.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.88 | 1.88 |
| 52 Week Low | $31.65 | $3.97 |
| 52 Week High | $77.55 | $20.26 |
| Indicator | PAR | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 73.61 |
| Support Level | $36.48 | $17.11 |
| Resistance Level | $38.50 | $18.29 |
| Average True Range (ATR) | 1.38 | 0.94 |
| MACD | 0.25 | 0.11 |
| Stochastic Oscillator | 81.57 | 80.68 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.